Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Its clinical development services include medical affairs, clinical trial management, feasibility and start-up study, clinical monitoring, global regulatory affairs, medical writing, biometrics, pharmacovigilance, core laboratory, and quality assurance. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MEDP
CUSIPN/A
Phone513-579-9911
Debt
Debt-to-Equity Ratio0.32
Current Ratio0.68
Quick Ratio0.68
Price-To-Earnings
Trailing P/E Ratio37.59
Forward P/E Ratio23.43
P/E Growth1.5
Sales & Book Value
Annual Sales$436.15 million
Price / Sales4.66
Cash Flow$2.5614 per share
Price / Cash22.32
Book Value$15.18 per share
Price / Book3.77
Profitability
EPS (Most Recent Fiscal Year)$1.52
Net Income$39.12 million
Net Margins10.44%
Return on Equity14.22%
Return on Assets7.79%
Miscellaneous
Employees2,500
Outstanding Shares35,570,000
Market Cap$2.09 billion
Medpace (NASDAQ:MEDP) Frequently Asked Questions
What is Medpace's stock symbol?
Medpace trades on the NASDAQ under the ticker symbol "MEDP."
How were Medpace's earnings last quarter?
Medpace Holdings Inc (NASDAQ:MEDP) released its quarterly earnings results on Tuesday, July, 31st. The company reported $0.61 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.42 by $0.19. The firm had revenue of $117.80 million for the quarter, compared to the consensus estimate of $104.97 million. Medpace had a return on equity of 14.22% and a net margin of 10.44%. The company's revenue for the quarter was up 24.5% on a year-over-year basis. During the same period last year, the business posted $0.38 EPS. View Medpace's Earnings History.
When is Medpace's next earnings date?
What guidance has Medpace issued on next quarter's earnings?
Medpace issued an update on its FY18 earnings guidance on Monday, July, 30th. The company provided EPS guidance of $2.51-2.62 for the period, compared to the Thomson Reuters consensus estimate of $1.93. The company issued revenue guidance of $461-473 million, compared to the consensus revenue estimate of $431.46 million.
What price target have analysts set for MEDP?
8 brokerages have issued 12-month price targets for Medpace's shares. Their predictions range from $35.00 to $49.00. On average, they expect Medpace's share price to reach $38.80 in the next year. This suggests that the stock has a possible downside of 32.1%. View Analyst Price Targets for Medpace.
What is the consensus analysts' recommendation for Medpace?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Medpace.
Who are some of Medpace's key competitors?
Some companies that are related to Medpace include Icon (ICLR), PRA Health Sciences (PRAH), EXACT Sciences (EXAS), Exelixis (EXEL), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Intrexon (XON), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), Pieris Pharmaceuticals (PIRS), VIRALYTICS Ltd/S (VRACY) and Anavex Life Sciences (AVXL).
Who are Medpace's key executives?
Medpace's management team includes the folowing people:
- Dr. August James Troendle, Chairman, Pres & CEO (Age 62)
- Mr. Jesse J. Geiger, CFO & Chief Operating Officer of Laboratory Operations (Age 44)
- Ms. Susan E. Burwig, Exec. VP of Operations (Age 55)
- Mr. Stephen P. Ewald, Gen. Counsel & Corp. Sec. (Age 49)
- Mr. Todd Meyers, VP of Bus. Devel. and Marketing
When did Medpace IPO?
(MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.
Has Medpace been receiving favorable news coverage?
News coverage about MEDP stock has trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Medpace earned a media and rumor sentiment score of 0.16 on Accern's scale. They also gave media headlines about the company an impact score of 46.31 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. View Recent Headlines for Medpace.
Who are Medpace's major shareholders?
Medpace's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.52%), Acadian Asset Management LLC (3.61%), Laurion Capital Management LP (1.91%), Bernzott Capital Advisors (1.37%), Renaissance Technologies LLC (0.95%) and Dimensional Fund Advisors LP (0.91%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Limited Partnership and Susan E Burwig. View Institutional Ownership Trends for Medpace.
Which major investors are selling Medpace stock?
MEDP stock was sold by a variety of institutional investors in the last quarter, including Bernzott Capital Advisors, Federated Investors Inc. PA, Virginia Retirement Systems ET AL, Fisher Asset Management LLC, Convergence Investment Partners LLC, Systematic Financial Management LP and Strs Ohio. Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger and Medpace Limited Partnership. View Insider Buying and Selling for Medpace.
Which major investors are buying Medpace stock?
MEDP stock was purchased by a variety of institutional investors in the last quarter, including Laurion Capital Management LP, BlackRock Inc., Acadian Asset Management LLC, Chartwell Investment Partners LLC, Renaissance Technologies LLC, Citadel Advisors LLC, Dimensional Fund Advisors LP and Janus Henderson Group PLC. Company insiders that have bought Medpace stock in the last two years include August J Troendle and Susan E Burwig. View Insider Buying and Selling for Medpace.
How do I buy shares of Medpace?
Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Medpace's stock price today?
One share of MEDP stock can currently be purchased for approximately $57.17.
How big of a company is Medpace?
Medpace has a market capitalization of $2.09 billion and generates $436.15 million in revenue each year. The company earns $39.12 million in net income (profit) each year or $1.52 on an earnings per share basis. Medpace employs 2,500 workers across the globe.
How can I contact Medpace?
Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]
MarketBeat Community Rating for Medpace (NASDAQ MEDP)
MarketBeat's community ratings are surveys of what our community members think about Medpace and other stocks. Vote "Outperform" if you believe MEDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEDP will underperform the S&P 500 over the long term. You may vote once every thirty days.
